CORRECTION article

Front. Drug Discov., 17 April 2024

Sec. Anti-Cancer Drugs

Volume 4 - 2024 | https://doi.org/10.3389/fddsv.2024.1397200

Corrigendum: Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Article metrics

View details

884

Views

319

Downloads

In the published article, there was an error in the Author list, and author Xiaozhi Lv was erroneously listed as the third author, not the first. The corrected Author list appears below.

“Xiaozhi Lv, Junyan Wu*, Herui Yao*, Suiwen Ye, Nan Zhang”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

In the published article, there was an error in the Funding statement. It was erroneously left out. The correct Funding statement appears below.

Statements

Funding

The authors declare that financial support was received for the research, authorship, and/or publication of this article. Funding went to principal investigator JW for the name of the clinical trial sponsor—itraconazole against SHR6390 in healthy subjects trial. This study was funded by Jiangsu Hengrui Pharmaceutical Co., Ltd. The involvement of funder in the study is as follows: the funders only participated in the design of national clinical trials, and the subsequent data collection, analysis and interpretation were all completed by the researchers of our center. The funders did not participate in the writing of this paper or the decision of whether to publish it.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

SHR6390, itraconazole, pharmacokinetic, safety, drug-drug interaction, healthy subjects

Citation

Lv X, Wu J, Yao H, Ye S and Zhang N (2024) Corrigendum: Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390. Front. Drug Discov. 4:1397200. doi: 10.3389/fddsv.2024.1397200

Received

20 March 2024

Accepted

08 April 2024

Published

17 April 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

4 - 2024

Updates

Copyright

*Correspondence: Junyan Wu, ; Herui Yao,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics